[1]曹琳,刘超.妊娠糖尿病诊疗的争议与共识[J].国际内分泌代谢杂志,2016,36(03):176-179.[doi:10.3760/cma.j.issn.1673-4157.2016.03.08]
　Cao Lin,Liu Chao..Controversy and concensus on the diagnosis and treatment of gestational diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(03):176-179.[doi:10.3760/cma.j.issn.1673-4157.2016.03.08]
点击复制

妊娠糖尿病诊疗的争议与共识()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年03期
页码:
176-179
栏目:
综述
出版日期:
2016-05-20

文章信息/Info

Title:
Controversy and concensus on the diagnosis and treatment of gestational diabetes mellitus
作者:
曹琳; 刘超
210028 南京中医药大学附属中西医结合医院内分泌代谢病院区,江苏省中医药研究所
Author(s):
Cao Lin;  Liu Chao.
Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine,Nanjing 210028, China
关键词:
妊娠糖尿病;  诊断;  治疗
Keywords:
Gestational diabetes mellitus;  Diagnosis;  Treatment
DOI:
10.3760/cma.j.issn.1673-4157.2016.03.08
摘要:
妊娠糖尿病(GDM)的发病率逐年升高,其与不良妊娠结局及母婴长期并发症密切相关。早期筛查与诊断至关重要。但目前GDM筛查时间、筛查方法及诊断标准尚未统一。从药物的安全性考虑,以往认为胰岛素是GDM治疗的首选,且新型胰岛素类似物因其更好的血糖控制和低血糖发生率低而受到推崇。但晚近的研究显示,口服降糖药(格列本脲和二甲双胍)同样安全有效,可作为GDM的一线用药。
Abstract:
The incidence of gestational diabetes mellitus(GDM)is increasing. This disorder is associated with adverse pregnancy outcomes and has long-term implications for both mother and child. Early screening and diagnosis are very crucial. However, there is no agreement regarding to the screening time, method and the diagnostic criteria for GDM. From the aspect of safety, insulin therapy is previously considered as the first choice of pharmacotherapy for GDM. Newly insulin analogs are preferred due to better glycemic control and lower risks of hypoglycemia. Recent studies have shown that oral anti-diabetic agents such as glyburide and metformin are safe and can be used as first-line therapy for patients with GDM.

参考文献/References:

[1] American Diabetes Association. Standards of medical care in diabetes-2014[J].Diabetes Care,2014, 37(Suppl 1): S14-S80. DOI: 10.2337/dc14-S014.
[2] Falavigna M, Prestes I, Schmidt MI, et al. Impact of gestational diabetes mellitus screeningstrategies on perinatal outcomes: a simulation study[J]. Diabetes Res Clin Pract, 2013, 99(3): 358-365. DOI: 10.1016/j.diabres.2012.12.009.
[3] National Collaborating Centre for Women's and Children's Health(UK). Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. 2015. London:National Institute for Health and Care Excellence.
[4] Alwan N, Tuffnell DJ, West J. Treatments for gestational diabetes[J]. Cochrane Database Syst Rev, 2009, 8(3): CD003395. DOI:10.1002/14651858.CD003395.pub2.
[5] Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women[J].Diabetes Care, 2007, 30(4):771-776. DOI:10.1002/dmrr.271.
[6] Lloyd A, Townsend C,Munro V, et al. Cost-effectiveness of insulin aspart compared to human insulin in pregnant women with type 1 diabetes in the UK[J]. Curr Med Res Opin, 2009, 25(3): 599-605. DOI:10.1185/03007990802668208.
[7] Mathiesen ER, Hod M,Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes[J]. Diabetes Care, 2012, 35(10): 2012-1017. DOI:10.2337/dc11-2264.
[8] Poomalar GK. Changing trends in management of gestational diabetes mellitus[J].World J Diabetes,2015, 6(2): 284-295. DOI:10.4239/wjd.v6.i2.284.
[9] Combs CA. Continuous glucose monitoring and insulin pump therapy for diabetes in pregnancy[J]. J Matern Fetal Neonatal Med, 2012, 25: 2025-2027. DOI:10.3109/14767058.2012.670409.
[10] Committee on Practice Bulletins-Obstetrics. Practice Bulletin No.137: Gestational diabetes mellitus[J]. Obstet Gynecol,2013,122(2 Pt 1): 406-416. DOI: 10.1097/01.AOG.0000433006.09219.f1.
[11] Walker JD. NICE guidance on diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. NICE clinical guideline 63[J]. Diabet Med,2008, 25(9): 1025-1027. DOI: 10.1111/j.1464-5491.2008.02532.x.
[12] Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes[J].N Engl J Med, 2008, 358: 2003-2015. DOI: 10.1056/NEJMoa0707193.
[13] Su DF, Wang XY. Metformin vs. insulin in the management of gestational diabetes: a systematic review and meta-analysis[J]. Diabetes Res Clin Pract,2014, 104(3): 353-357. DOI: 10.1016/j.diabres.
[14] Marques P, Carvalho MR, Pinto L, et al. Metformin safety in the management of gestational diabetes[J]. Endocr Pract,2014, 20(10): 1022-1031. DOI:10.4158/EP14018.OR.
[15] Rowan JA, Rush EC, Obolonkin V, et al. Metformin in gestational diabetes: the offspring follow-up(MiG TOFU): body composition at 2 years of age[J]. Diabetes Care, 2011, 34(10): 2279-2284. DOI:10.2337/dc11-2241.
[16] Silva JC, Pacheco C, Bizato J, et al. Metformin compared with glyburide for the management of gestational diabetes[J]. Int J Gynaecol Obstet, 2010, 111(1): 37-40. DOI:10.1016/j.ijgo.2010.04.028.
[17] Kavitha N, De S, Kanagasabai S. Oral hypoglycemic agents in pregnancy: an update[J]. J Obstet Gynaecol India, 2013, 63: 82-87.DOI: 10.1007/s13224-012-0312-z.
[18] Zeng YC, Li MJ, Chen Y, et al. The use of glyburide in the management of gestational diabetes mellitus: a meta-analysis[J]. Adv Med Sci,2014, 59(1): 95-101.DOI: 10.1016/j.advms.
[19] Nicholson W, Bolen S, Witkop CT, et al. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review[J]. Obstet Gynecol,2009, 113(1):193-205.DOI: 10.1097/AOG.0b013e318190a459.
[20] Rowan JA, Gao W, Hague WM, et al. Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial[J]. Diabetes Care, 2010, 33(1):9-16.DOI:10.2337/dc09-1407.
[21] Hernandez TL, Friedman JE, Van Pelt RE, et al. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged?[J]. Diabetes Care, 2011, 34(7):1660-1668. DOI:10.2337/dc11-0241.

相似文献/References:

[1]孙敏讷,段宇.老年亚临床甲状腺功能减退症的诊治特点[J].国际内分泌代谢杂志,2014,(06):411.[doi:10.3760/cma.j.issn.1673-4157.2014.06.014]
　Sun Minne,Duan Yu..Diagnositc and therapeutic characteristics of subclinical hypothyroidism in elderly people[J].International Journal of Endocrinology and Metabolism,2014,(03):411.[doi:10.3760/cma.j.issn.1673-4157.2014.06.014]
[2]胡欣 陈国芳 刘超.男性迟发型性腺功能减退症的诊断与治疗[J].国际内分泌代谢杂志,2015,(01):59.[doi:10.3760/cma.j.issn.1673-4157.2015.01.015]
　Hu Xin,Chen Guofang,Liu Chao..Diagnosis and therapeutic options for late-onset hypogonadism in men[J].International Journal of Endocrinology and Metabolism,2015,(03):59.[doi:10.3760/cma.j.issn.1673-4157.2015.01.015]
[3]乔艳花,张丹丹,王倩.妊娠糖尿病与甲状腺自身免疫的相关性研究[J].国际内分泌代谢杂志,2015,(04):242.[doi:10.3760/cma.j.issn.1673-4157.2015.04.007]
　Qiao Yanhua,Zhang Dandan,Wang Qian..Relationship between gestational diabetes and thyroid autoimmunity[J].International Journal of Endocrinology and Metabolism,2015,(03):242.[doi:10.3760/cma.j.issn.1673-4157.2015.04.007]
[4]霍琰,刘素新,张文辉,等.Visfatin在妊娠糖尿病孕妇血清及胎盘组织中的表达[J].国际内分泌代谢杂志,2014,(05):300.[doi:10.3760/cma.j.issn.1673-4157.2014.05.003]
　Huo Yan,Liu Suxin,Zhang Wenhui,et al.Circulating levels of visfatin and its expression in placental tissue in pregnant women with gestational diabetes[J].International Journal of Endocrinology and Metabolism,2014,(03):300.[doi:10.3760/cma.j.issn.1673-4157.2014.05.003]
[5]王锐 陆强 王术艺 朱东林 蒋韬 马宁 刘悦 李燕莉 贾晓娇 姚立新.血清25羟维生素D及vaspin水平与妊娠糖尿病关系的研究[J].国际内分泌代谢杂志,2015,(05):306.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.005]
　Wang Rui,Lu Qiang,Wang Shuyi,et al.Relationship between serum 25-hydroxyvitamin D, vaspin and gestational diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):306.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.005]
[6]刘晓蓉 朱德发.糖尿病下肢动脉病变的诊断与治疗[J].国际内分泌代谢杂志,2015,(05):327.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.010]
　Liu Xiaorong*,Zhu Defa..Diagnosis and treatment of lower extremity arterial disease in diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):327.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.010]
[7]毛斐,鹿斌,李益明.SUDOSCAN对糖尿病周围神经病变的诊断价值[J].国际内分泌代谢杂志,2016,36(05):331.[doi:10.3760/cma.j.issn.1673-4157.2016.05.12]
　Mao Fei,Lu Bin,Li Yiming.Diagnostic value of SUDOSCAN in detecting diabetic peripheral neuropathy[J].International Journal of Endocrinology and Metabolism,2016,36(03):331.[doi:10.3760/cma.j.issn.1673-4157.2016.05.12]
[8]郑仁东,刘超.糖尿病合并男性性腺功能减退症的识别与处理[J].国际内分泌代谢杂志,2016,36(06):394.[doi:10.3760/cma.j.issn.1673-4157.2016.06.09]
　Zheng Rendong,Liu Chao..Recognition and treatment of diabetes with male hypogonadism[J].International Journal of Endocrinology and Metabolism,2016,36(03):394.[doi:10.3760/cma.j.issn.1673-4157.2016.06.09]
[9]刘颖丰,刘芳.角膜共聚焦显微镜对糖尿病周围神经病变的诊断价值[J].国际内分泌代谢杂志,2017,37(03):178.[doi:10.3760/cma.j.issn.1673-4157.2017.03.009]
　Liu Yingfeng,Liu Fang..Diagnostic value of corneal confocal microscopy on diabetic peripheral neuropathy[J].International Journal of Endocrinology and Metabolism,2017,37(03):178.[doi:10.3760/cma.j.issn.1673-4157.2017.03.009]
[10]曹白露,邵加庆.SUDOSCAN在糖尿病微血管并发症早期诊断 及治疗评估中的作用[J].国际内分泌代谢杂志,2017,37(06):401.
　Cao Bailu,Shao Jiaqing..The value of SUDOSCAN in the early diagnosis and evaluation of diabetic microvascular complications[J].International Journal of Endocrinology and Metabolism,2017,37(03):401.

更新日期/Last Update: 2016-05-20